Vivos Therapeutics (VVOS) Projected to Post Earnings on Wednesday

Vivos Therapeutics (NASDAQ:VVOS) will likely be releasing its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect Vivos Therapeutics to post earnings of ($0.39) per share and revenue of $3.37 million for the quarter.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.01). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $3.63 million. Vivos Therapeutics had a negative return on equity of 170.43% and a negative net margin of 76.82%. During the same quarter in the previous year, the company earned ($1.63) earnings per share. On average, analysts expect Vivos Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vivos Therapeutics Price Performance

Vivos Therapeutics stock opened at $4.58 on Tuesday. The stock has a market cap of $26.98 million, a P/E ratio of -2.65 and a beta of 7.03. Vivos Therapeutics has a 1 year low of $1.98 and a 1 year high of $7.95. The firm’s 50 day moving average price is $4.13 and its 200-day moving average price is $3.42.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Alliance Global Partners lowered shares of Vivos Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, May 20th. Wall Street Zen downgraded Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. Industrial Alliance Securities set a $2.25 target price on Vivos Therapeutics in a research report on Tuesday, May 20th. Finally, Ascendiant Capital Markets decreased their target price on Vivos Therapeutics from $6.60 to $6.20 and set a “buy” rating for the company in a research report on Tuesday, April 15th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.